Literature DB >> 26030710

Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.

Klaus Strebhardt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26030710      PMCID： PMC5242295          DOI： 10.1080/15384101.2015.1056611

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Long Chen; Hexiang Wang; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

3.  Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.

Authors:  Monika Raab; Andrea Krämer; Stephanie Hehlgans; Mourad Sanhaji; Elisabeth Kurunci-Csacsko; Christina Dötsch; Gesine Bug; Oliver Ottmann; Sven Becker; Fiona Pachl; Bernhard Kuster; Klaus Strebhardt
Journal:  Mol Oncol       Date:  2014-08-11       Impact factor: 6.603

Review 4.  Targeting polo-like kinase 1 for cancer therapy.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

5.  Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.

Authors:  Xianzeng Hou; Zhiguo Li; Weize Huang; Jiejie Li; Christopher Staiger; Shihuan Kuang; Tim Ratliff; Xiaoqi Liu
Journal:  Prostate       Date:  2013-05-09       Impact factor: 4.104

6.  Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

Authors:  Monika Raab; Sven Kappel; Andrea Krämer; Mourad Sanhaji; Yves Matthess; Elisabeth Kurunci-Csacsko; Julia Calzada-Wack; Birgit Rathkolb; Jan Rozman; Thure Adler; Dirk H Busch; Irene Esposito; Helmut Fuchs; Valérie Gailus-Durner; Martin Klingenspor; Eckhard Wolf; Nicole Sänger; Florian Prinz; Martin Hrabě de Angelis; Jost Seibler; Juping Yuan; Martin Bergmann; Rainald Knecht; Bertolt Kreft; Klaus Strebhardt
Journal:  Nat Commun       Date:  2011-07-19       Impact factor: 14.919

7.  Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells.

Authors:  Monika Raab; Fiona Pachl; Andrea Krämer; Elisabeth Kurunci-Csacsko; Christina Dötsch; Rainald Knecht; Sven Becker; Bernhard Kuster; Klaus Strebhardt
Journal:  Cell Res       Date:  2014-07-01       Impact factor: 25.617
  7 in total
  2 in total

1.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

2.  The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan.

Authors:  Khayal Gasimli; Monika Raab; Sven Becker; Mourad Sanhaji; Klaus Strebhardt
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.